Patient Advocacy

GSK has agreed to acquire Nuvalent in a deal that secures two next-generation NSCLC inhibitors under active FDA review with potential year-end launches.

David Coman, CEO, BGBx, explains how the firm's rebranding reflects a broader shift in biopharma commercialization, where integrating consulting, communications, and a three-dimensional science framework is increasingly necessary for companies.

The Supreme Court ruled unanimously in favor of Hikma Pharmaceuticals, finding its generic Vascepa did not infringe Amarin's patents under the skinny-label pathway, a decision that strengthens legal protections for generic manufacturers.

Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating a months-long standoff with the American Hospital Association and prompting calls for federal intervention.

WHO identifies experimental therapies from Mapp Biopharmaceutical, Regeneron, and Gilead as leading candidates for the Bundibugyo strain of Ebola virus disease, as the agency pushes for urgent clinical trials amid a growing outbreak.

Research published this week highlights tirzepatide outperforming other GLP-1 therapies in early type 2 diabetes treatment while separate studies identified autoantibodies as a likely biological driver behind persistent neurological symptoms in some long Covid patients.

Eli Lilly reported late-stage data showing patients with obesity were able to maintain long-term weight loss after transitioning from higher-dose injectable incretin therapies to lower-dose Zepbound or the company’s oral GLP-1 candidate Foundayo.

In an exclusive Q&A, Dean Erhardt discusses how fragmented onboarding processes delay therapy starts, along with noting how poor communication, limited visibility, and system misalignment is driving patient disengagement.

FDA advisory panel backs Truqap combination in PTEN-deficient prostate cancer, signaling potential expansion into biomarker-defined mHSPC population with limited treatment options.

Inizio launches integrated hub services model to streamline patient access, reimbursement, and adherence, reflecting a broader industry shift toward data-driven, end-to-end patient support strategies.

A report from American Society of Health-System Pharmacists projects U.S. prescription drug spending to surpass $1T in 2026, driven largely by surging demand for GLP-1 weight-loss therapies.

ARS Pharmaceutical’s CEO discusses how reformulating drugs and updating delivery design can improve the rate of patient adherence to medication.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, discusses how the Tecvayli and Darzalex Faspro combination delivers deep, durable responses, along with its rapid FDA review.

New studies from 23andMe suggest genetic variation may modestly influence GLP-1 weight-loss response and side effects.

A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.

The importance of aligning cost control with clinical appropriateness and continuity of care.

Jeanne Marrazzo, MD, FIDSA, MPH, CEO of the Infectious Diseases Society of America discusses the growing measles outbreak in the United States, which has surpassed 730 cases and represents the largest surge in decades.

A nationally representative survey of more than 20,000 U.S. adults found that 33% made at least one daily spending trade-off to pay for healthcare in the past year

Testing reveals that compounded tirzepatide products mixed with vitamin B12 contain a chemical impurity of unknown toxicity.

Public Citizen’s lawsuit highlights broader concerns over government transparency and oversight in pharmaceutical policy.

Both the AAP and CDC released their respective childhood vaccine guidance’s, including different vaccine administration recommendations, age limits, and combined vaccines.

Catalyst’s executive director of patient advocacy discusses the company’s new undergraduate program that provides participants with real-world experience in advocacy.

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.

Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing menopause and improving their health options.

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction issues.